Programs & products | Innate Pharma

Start of Phase I clinical trial of monalizumab in combination with durvalumab

February 8, 2016

Multicenter, open-label, dose-escalation and cohort-expansion Phase I study of durvalumab in combination with monalizumab in patients with solid tumors; Trial performed by AstraZeneca/MedImmune in the...

Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology

January 11, 2016

Research collaboration and licensing agreement for new bispecific antibodies using Innate Pharma’s technology and Sanofi’s technology and tumor targets Innate Pharma eligible for up to €400m in...

Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program

January 10, 2016

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a...

IPH5201

What is IPH5201?

IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway.
CD39 is an extracellular membrane-bound enzyme that is expressed on both tumor infiltrating immune cells and stromal cells, in several cancer types.

Read more about IPH5201

Fourth clinical trial opened with monalizumab (IPH2201)

December 17, 2015

Phase Ib/II trial testing monalizumab in combination with cetuximab in patients with relapsed or refractory head and neck cancer Trial conducted in Europe and the United States Innate Pharma SA (the...

First patient dosed in Phase I trial of IPH4102

December 3, 2015

Proprietary, new cytotoxic anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL); Orphan drug designation in the European Union; Innate’s third first-in...

Innate Pharma receives development milestone payment from Bristol-Myers Squibb

October 14, 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announced that it has received a US$5 million milestone payment from Bristol-Myers Squibb as part of the lirilumab licencing...

Opening of the Phase I/II trial of IPH2201 in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia

October 6, 2015

Third trial opened in the Phase II clinical program of IPH2201 - program rollout on track Trial conducted in the United States with leading investigator at OSU Innate Pharma SA (the “Company” -...

First patient treated in phase I/II trial with IPH2201 in ovarian cancer

September 28, 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the first patient was treated in the Phase I/II trial testing IPH2201, a first-in-class NKG2A checkpoint...

Presentation of IPH4102 rationale and phase I design at the cutaneous lymphoma task force meeting of the EORTC

September 26, 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer...

Subscribe to Programs & products

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers